Novartis New Organizational Model
Novartis has transformed into a focused medicines company,
and delivered consistent performance
Our strategy
Focused medicines company powered by technology leadership in R&D,
world-class commercialization, global access and data science
Portfolio simplification
in parallel
Delivered strong performance &
returned capital to shareholders
Exit of Animal Health,
Vaccines, Consumer Health
Alcon spin-off
Sale of Roche stake, returning majority of
proceeds to shareholders through a buyback
Sandoz strategic review
USD 31bn in M&A / BD&L since 2018
strengthening Innovative Medicines (IM)
portfolio
Consistent IM top-line growth:
7% sales CAGR from 2018-2021
Consistent IM bottom-line delivery:
13% Core Oplnc CAGR and
4ppts margin improvement since 2018
Innovation capability expansion;
built strengths in cell & gene, RNAi,
radioligand therapy
USD 36bn in share buybacks and
dividends from 2018-2021
Source: Novartis Annual Report. Constant currencies (cc) and core results are non-IFRS measures. An explanation of our non-IFRS measures can be found in our Condensed Financial Report for Q4 and FY 2021, published February 2, 2022.
4
NOVARTIS NEW ORGANIZATIONAL MODEL | APRIL 04, 2022 | NOVARTIS INVESTOR PRESENTATION
NOVARTIS | Reimagining MedicineView entire presentation